Clarke Capital Partners
Also known as Clarke Capital
Provo, Utah family office of Clearlink founder James Clarke, now presented as a growth-stage venture firm backing software, consumer and healthcare companies; led Biolexis' $10M Series A in 2023.
USEFUL FOR Founders · Business owners seeking a long-term partner · Co-investors
Provo, Utah family office and investment firm of Clearlink founder James Clarke. Unrelated to other firms using the 'Clarke Capital' name.
Family & background
- FAMILY
- Clarke
- WEALTH ORIGIN
- Clearlink (digital marketing company founded in 2001 and sold in 2011)
- HEADQUARTERS
- Provo, United States
- OUTSIDE CAPITAL
- Yes — also manages others' money
Investment approach
- STAGES
- Series ASeries BGrowthBuyout
- ROUTES
- Direct investments
- STRATEGIES
- Direct investmentsVenture capital
- LATEST DEAL
- Biolexis Therapeutics (Series A) · Nov 2023
- INBOUND
- Accepts submissions
Overview
Clarke Capital Partners was founded by James Clarke, who started Clearlink in 2001 and led it until its 2011 sale. His Brigham Young University advisory-board biography describes Clarke Capital Partners as a family office and investment firm headquartered in Provo, Utah, and a 2019 Silicon Slopes event listing described it as a family office investing in leveraged buyouts, intellectual property portfolios, university-licensed or acquired technologies and fast-growing founder-run businesses. Its current website presents the firm as a growth-stage venture firm partnering with founders across software, consumer and healthcare, leading or co-leading rounds from Series B onward through IPO and exit, with stated focus areas spanning Series A to pre-IPO. In January 2022 it purchased a significant stake in Clearlink, with Sitel Group remaining majority shareholder and Clarke returning as Clearlink's CEO, and in November 2023 it led the $10M Series A of Biolexis Therapeutics. Its website's selected portfolio lists HireVue, Clearlink, Contour, BoardCo, PetIQ, Biolexis Therapeutics and Montigen Pharmaceuticals.
Investment thesis
Backs founder-led companies in enterprise and vertical software, AI-native applications and cloud infrastructure, category-defining consumer brands and digital-first retail, and digital health and medical technology, plus profitable or near-profitable growth-equity situations, with partners who have operated companies themselves.
Holdings & investments (7)
- Biolexis TherapeuticsNOTABLEBiotech & Life Sciences · since 2023
- ClearlinkNOTABLEsince 2022
- HireVueNOTABLESoftware & SaaS
- PetIQConsumer & E-commerce
- Montigen PharmaceuticalsBiotech & Life Sciences · Acquired
- BoardCoConsumer & E-commerce
- ContourConsumer & E-commerce
People
Classification
Family-anchored Fund. Started with one family's capital but now also manages money for third parties. How family capital is classified →
FAQ
Clarke Capital Partners is a family-anchored fund based in Provo, the United States.
Clarke Capital Partners invests on behalf of the Clarke family (Clearlink (digital marketing company founded in 2001 and sold in 2011)).
Clarke Capital Partners invests directly in companies. Its stated asset mix includes direct investments and venture capital.
Clarke Capital Partners invests at Series A, Series B, Growth and Buyout stages in Software & SaaS, Consumer & E-commerce, HealthTech and Biotech & Life Sciences.
Key people at Clarke Capital Partners include James Clarke (Founder and Managing Partner), Tyler Hartmann (Partner), James Harrison (Operating Partner) and Mitch Mann (Operating Partner).
Clarke Capital Partners's holdings and investments include Biolexis Therapeutics, Clearlink, HireVue, PetIQ, Montigen Pharmaceuticals, BoardCo and Contour.
The most recent publicly reported investment by Clarke Capital Partners is Biolexis Therapeutics (Series A), announced in Nov 2023.
Clarke Capital Partners states that it accepts submissions.
Yes. Clarke Capital Partners manages capital from outside investors.